Navigation Links
DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America

WILMINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology announced today that it has been named to Deloitte's 2010 Technology Fast 500 list.  For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America.  Rankings are based on percentage of fiscal year revenue growth during the period 2005-2009.  DUSA grew annual revenues by 163% during this period.

"DUSA is honored to receive this recognition from Deloitte for the third year in a row," said Bob Doman, DUSA's President and Chief Executive Officer.  "This is a testament to all of the dedicated DUSA employees who, over the years, have contributed to making our Levulan® Photodynamic Therapy (PDT) one of the fastest growing procedures in dermatology."

Levulan PDT is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5 million treatment visits per year.  Through the first six months of 2010, U.S. Levulan revenue grew 34% over the prior year six months.

Technology Fast 500 Selection and Qualifying Criteria

Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.  This ranking is compiled from nominations submitted directly to the Technology Fast 500 website, and public company database research.  Technology Fast 500 award winners for 2010 are selected based on percentage fiscal year revenue growth during the five year period from 2005 to 2009.

To be considered, Technology Fast 500 entrants must meet the following criteria:

  • Must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues.
  • Base-year operating revenues must be at least $50,000 USD or CD, and current-year operating revenues must be at least $5 million USD or CD.
  • Be in business a minimum of five years.
  • Be headquartered in North America.

About Actinic Keratoses

Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight.  They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms.  They form on the outermost layer of skin and they can range in color from skin toned to reddish brown.  They can also range in size from as small as a pinhead to larger than a quarter.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products.  Levulan® Kerastick® for topical solution plus DUSA's BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.  DUSA also markets other dermatology products, including the BLU-U without Levulan and ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at

SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
2. Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
4. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
5. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
6. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
7. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
8. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
9. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
10. Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
11. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... Intellitec Solutions announced today that they have ... as Microsoft’s official group for end users of Dynamics SL ERP software, the ... experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to the ...
(Date:11/27/2015)... ... 27, 2015 , ... The moment you stop improving is ... fulfilling the needs of advisers and clients but going above and beyond to ... customer service. However, there's always room for improvement, which is why the entire ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College ... Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD ... colleges, as only one of twelve colleges and universities in the state of California ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into its ... 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will ...
Breaking Medicine News(10 mins):